ATE202145T1 - Nukleinsäure-einbringungssystem - Google Patents

Nukleinsäure-einbringungssystem

Info

Publication number
ATE202145T1
ATE202145T1 AT95937039T AT95937039T ATE202145T1 AT E202145 T1 ATE202145 T1 AT E202145T1 AT 95937039 T AT95937039 T AT 95937039T AT 95937039 T AT95937039 T AT 95937039T AT E202145 T1 ATE202145 T1 AT E202145T1
Authority
AT
Austria
Prior art keywords
nucleic acid
delivery system
acid delivery
transfer system
protein
Prior art date
Application number
AT95937039T
Other languages
English (en)
Inventor
Winfried Wels
Jesus Fominaya
Original Assignee
Winfried Wels
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winfried Wels filed Critical Winfried Wels
Application granted granted Critical
Publication of ATE202145T1 publication Critical patent/ATE202145T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95937039T 1994-11-01 1995-10-31 Nukleinsäure-einbringungssystem ATE202145T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810627 1994-11-01
PCT/EP1995/004270 WO1996013599A1 (en) 1994-11-01 1995-10-31 Nucleic acid transfer system

Publications (1)

Publication Number Publication Date
ATE202145T1 true ATE202145T1 (de) 2001-06-15

Family

ID=8218332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937039T ATE202145T1 (de) 1994-11-01 1995-10-31 Nukleinsäure-einbringungssystem

Country Status (8)

Country Link
US (1) US6498233B1 (de)
EP (1) EP0789776B1 (de)
JP (1) JPH09511916A (de)
AT (1) ATE202145T1 (de)
AU (1) AU695196B2 (de)
DE (1) DE69521331T2 (de)
NZ (1) NZ295673A (de)
WO (1) WO1996013599A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
IL130160A0 (en) * 1996-12-02 2000-06-01 Univ Wake Forest Inactivation of HIV co-receptors as therapy for HIV infection
AU7266698A (en) 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
EP1000163B1 (de) * 1997-07-11 2005-10-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services Pseudomonas exotoxin-a-ähnliche chimerische immunogene
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US6903077B1 (en) 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
FR2793414B1 (fr) * 1999-05-10 2003-05-23 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
DE19952957B4 (de) * 1999-11-03 2006-08-31 Acgt Progenomics Ag Modulare Transportsysteme für molekulare Substanzen und deren Herstellung und Verwendung
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
US7314625B2 (en) * 2000-12-21 2008-01-01 The United States As Represented By The Secretary Of The Department Of Health And Human Services Chimeric protein comprising non-toxic Pseudomonas exotoxin A and Type IV pilin sequences
US6846484B2 (en) * 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
JP2006517793A (ja) * 2003-01-31 2006-08-03 ノバルティス アクチエンゲゼルシャフト スクリーニングアッセイ
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US7205387B2 (en) * 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
EP1781777A1 (de) * 2004-07-02 2007-05-09 Avaris AB Verfahren zur genetischen aktivierung von zellen sowie verwendungen für die zellen
AU2005294436A1 (en) 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
US20070148131A1 (en) * 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
EP2150608B1 (de) 2007-05-07 2017-11-29 Protalix Ltd. Grossvolumiger einweg-bioreaktor
US7887801B2 (en) * 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
WO2011085178A1 (en) * 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
US9867777B2 (en) 2010-01-19 2018-01-16 Hanmi Science Co., Ltd. Liquid formulations for long-acting G-CSF conjugate
US9321847B2 (en) * 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
US9095624B2 (en) 2011-05-23 2015-08-04 Contango Partners Group, Inc. Modular transport platform for targeted delivery of therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
DE4339922C1 (de) * 1993-09-03 1994-10-06 Max Planck Gesellschaft Vektor für Leber-Gentherapie
EP0753069A1 (de) * 1994-04-15 1997-01-15 Targeted Genetics Corporation Fusionsprotein für Gentransfer

Also Published As

Publication number Publication date
JPH09511916A (ja) 1997-12-02
EP0789776A1 (de) 1997-08-20
AU3926895A (en) 1996-05-23
NZ295673A (en) 1999-03-29
WO1996013599A1 (en) 1996-05-09
DE69521331D1 (de) 2001-07-19
US6498233B1 (en) 2002-12-24
AU695196B2 (en) 1998-08-06
DE69521331T2 (de) 2001-09-20
EP0789776B1 (de) 2001-06-13

Similar Documents

Publication Publication Date Title
DE69521331D1 (de) Nukleinsäure-einbringungssystem
MX9800719A (es) Proteinas de transporte y sus usos.
HRP20030088B1 (hr) Anti-dvostruka integrinska protutijela, pripravci, postupci i primjena
DE69638142D1 (de) Regulierte Gene und ihre Verwendungen
SE9803099D0 (sv) Nucleic acid transfer
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
ATE240738T1 (de) Verwendung von epithel-adhärente lactobazillen
ATE246516T1 (de) Neue enzyme und prodrugs für adept
HU9502920D0 (en) New bacillus thuringiensis strains and their insecticidal proteins
Hundal et al. Lack of ability of trypsin‐treated mitochondrial F1‐ATPase to bind the oligomycin‐sensitivity conferring protein (OSCP)
AR003407A1 (es) Procedimiento de clonacion de un acido nucleico que codifica una proteina con actividad de delta-5,7-esterol, delta-7-reductasa, procedimiento de preparacion de la proteina, procemiento de reduccion in vitro de un esterol insaturado, procedimiento de produccion de pregnenolona, cepa de levadura transformada y metodo de diagnostico in vitro para la deteccion de la deficiencia de delta-5, 7-esterol, delta-7-reductasa
FR2780062B1 (fr) Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
AU1060397A (en) High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
Rago et al. Staphylococcal exfoliative toxins cleave α-and β-melanocyte-stimulating hormones
DE59611307D1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
EP1023906A4 (de) Verstärker für antikörper gegen lymphoiden tumor
DK1002056T3 (da) ppGpp-syntease og ekspressionssystem til forbedret fremstilling af protein af interesse
AU2256197A (en) High affinity nucleic acid ligands of complement system proteins
Etherington et al. Investigation of the cathepsins of human gastric carcinomata
Roberts et al. The type II secretion system utilizes GspN for transport of lipoproteins to the Acinetobacter baumannii cell surface
CA2046598A1 (en) T-pa solubilisation
Iacono et al. Lysozyme binding by a polyglycerol phosphate polymer of the oral bacterium Streptococcus mutans BHT
Bhatti et al. Antigenic independence of the two types of alkaline phosphatases from Serratia marcescens strain 211
Stewart-Tull et al. Studies on the Vibrio cholerae mucmase complex. III. Neutralisation of the neuraminidase activity by specific anti-neuraminidase IgG
FR2734839B1 (fr) Sequence d'adn codant pour une proteine d'a. thaliana ayant une activite delta-5,7 sterol, delta-7 reductase, proteine delta-7red, procede de production, souches de levures transformees, applications.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties